Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19: Trump Still Hasn’t Pulled Trigger On Defense Production Act

Prez says the threat of company “nationalization” under the Defense Protection Act “sent tremors through our business community and through our country”

Executive Summary

President Trump still hasn’t used the Defense Production Act to address US medical device shortages despite invoking the law on 18 March. The DPA gives the government broad authority to, among other things, push manufacturers to make particular products in a time of great national need. At a 22 March press conference, Trump said he’s leery of doing that because “the concept of nationalizing our businesses is not a good concept. If you go the nationalization route, we’re going to tell a company to make a ventilator – they don’t even know what a ventilator is.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT126442

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel